Skip to main content
Premium Trial:

Request an Annual Quote

Genalice Teams up with Intel to Develop Products for the Sequencing Market


NEW YORK (GenomeWeb) – Dutch software company Genalice said this week that it has signed a product development partnership with Intel.

Under the terms of the agreement, Intel will be the main hardware supplier for Genalice. The partners will also work on optimizing the Genalice Map software to run on Intel Xeon Processors, the company said. Based on data from internal benchmarks, Genalice's software currently takes 24 hours each to map short reads from 42 human genomes and 42 tomato genomes when it's run on an Intel Xeon ES server. Moving forward, both companies will work on improving on these early results, according to Jos Lunenberg, Genalice's chief business officer.

Last week, Genalice announced that it had received a multimillion dollar capital investment from Redbrae, a consortium of US and UK-based private equity investors, to support product development and distribution. The company has not disclosed the exact amount of the investment.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.